Retatrutide is not FDA approved and tirzepatide is. That single sentence answers the question most people are actually asking when they search retatrutide vs tirzepatide, because the choice in 2026 is between a promising experimental drug you cannot legally or safely buy and an approved one with three years of real-world prescribing behind it. The trial data still matters, because it tells you where weight-loss medicine is heading and what questions to ask your clinician today. This guide walks through both drugs with the numbers, names the risks the gray market will not and explains what a patient on a flat-fee membership should do about either one.
- Retatrutide is a triple agonist acting on GIP, GLP-1 and glucagon receptors. It remains investigational with no FDA approval as of November 2026.
- In its phase 2 trial retatrutide produced average weight loss up to roughly 24 percent at 48 weeks on the highest dose studied.
- Tirzepatide is approved as Zepbound for weight management and Mounjaro for type 2 diabetes. The SURMOUNT-1 trial showed up to about 22.5 percent average weight loss at 72 weeks.
- There is no legal compounded retatrutide. Any vial sold online is unapproved, unverified and outside the FDA's safety system.
- A flat fee for the doctor with zero markup on the medicine means your cost never rises when a dose rises, whichever approved drug your clinician chooses.
What retatrutide actually is
Retatrutide is an investigational injection from Eli Lilly that activates three hormone receptors at once. Existing incretin drugs act on one or two. Semaglutide acts on the GLP-1 receptor alone. Tirzepatide acts on GLP-1 and GIP. Retatrutide adds a third action on the glucagon receptor, which is why researchers describe it as a triple agonist and why appetite suppression, insulin signaling and energy expenditure all appear to move together in its trial results.
The headline numbers come from a phase 2 trial published in the New England Journal of Medicine in 2023. Adults with obesity who took the highest retatrutide dose studied lost an average of roughly 24 percent of their body weight at 48 weeks. For context, bariatric surgery trials often report averages in the 25 to 30 percent range, which is why the metabolic medicine community paid attention.
A phase 2 result is a promise under investigation, not a product. Lilly moved retatrutide into phase 3 testing in the TRIUMPH program and those trials are still generating data. No regulator has reviewed a completed application for retatrutide. No label exists describing who should take it, at what dose or with what warnings. That last point deserves emphasis, because the absence of a label is the absence of the entire safety architecture you rely on when a pharmacy hands you a box.
What tirzepatide has already proven
Tirzepatide is the same molecule in two approved packages. As Mounjaro it treats type 2 diabetes. As Zepbound it treats obesity and, since late 2024, moderate to severe obstructive sleep apnea in adults with obesity. The SURMOUNT-1 trial published in the New England Journal of Medicine in 2022 followed adults with obesity for 72 weeks. Participants on the highest 15 mg dose lost an average of roughly 22.5 percent of their body weight, compared with about 3 percent on placebo. Gastrointestinal side effects, mainly nausea and diarrhea, were the most common reasons people adjusted or stopped dosing and they remain the main thing a careful clinician manages during titration.
Three years of real-world prescribing add what trials cannot. We know how the drug behaves in people taking it for two years, what happens when doses are held rather than escalated and how side effects settle with slower titration. Cash-pay pricing has also come down and stabilized. LillyDirect and major pharmacies have published self-pay vial pricing that commonly starts in the low hundreds per month for the lowest doses of Zepbound and lower doses are sufficient for many patients. That price is billed by the pharmacy and it changes with the dose, which is precisely why the structure of your doctor's fee matters more than the sticker on the vial.
The comparison, honestly stated
Retatrutide and tirzepatide side by side
November 2026
| Question | Retatrutide | Tirzepatide (Zepbound and Mounjaro) |
|---|---|---|
| FDA status | Investigational. Phase 3 trials ongoing | Approved for obesity and for type 2 diabetes |
| Best trial result | About 24 percent average weight loss at 48 weeks, phase 2 | About 22.5 percent average weight loss at 72 weeks, phase 3 |
| Safety profile | No completed regulatory review, no label | Label in place with known side effects and monitoring guidance |
| Legal compounded version | None exists | None exists either. Branded only |
| Available today | Only inside a clinical trial | At pharmacies nationwide |
The two percent gap between the headline numbers is smaller than it looks. Different trials, different durations and different populations make direct comparison unreliable and a 48-week average can still be climbing when a 72-week average has settled. What the data genuinely says is that retatrutide may eventually be the stronger drug and tirzepatide is the only one of the two you can actually get.


Why we will not sell you retatrutide today
Some telehealth platforms are already advertising retatrutide. Every one of those offers is a gray-market product, because there is no approved retatrutide for a pharmacy to dispense. When a drug is unapproved it cannot be legally compounded under US law either, so the vials being shipped are manufactured outside any FDA-inspected facility with no verification of what is inside them. The FDA has warned repeatedly about dosing errors and contaminated products from compounders selling unapproved GLP-1 copies. An investigational drug with no approved version to copy sits even further outside that system.
Our clinical protocols are built on one non-negotiable rule. We prescribe branded, FDA-approved medication only, so Wegovy, Zepbound, Ozempic, Mounjaro, Wegovy Tablets and Foundayo and never a compounded copy of any molecule. When retatrutide completes its trials, receives approval and becomes available through licensed pharmacies, it will enter the toolkit like every other approved option. Until then, prescribing it would mean handing you an unverified vial and calling that medicine. We will not do it.
The objection we hear most: why should I pay $598 before I even know which drug I will take
This is a fair objection and we answer it with the math rather than with reassurance. The Cardiometabolic Optimization Membership is one flat $299 a month for the doctor and the first charge at checkout is a single $598 that covers the first two months together. That charge includes your clinical intake, your first comprehensive Biomarker Audit and the clinical work of building your protocol. It is a two-month commitment to the doctor, not to any drug.
The order of operations is the point. We measure ApoB, Lp(a), hs-CRP, HbA1c, fasting insulin, full thyroid and hormone panels before a prescription conversation starts, because the right medication depends on what the labs show. A patient whose primary problem is insulin resistance, one whose appetite signal is the driver and one with a thyroid finding all need different plans. Deciding on a drug before the labs is how people end up on the wrong molecule at the highest dose.
Then there is the incentive question underneath. Many platforms earn money on the medication itself, so the dose that climbs is the revenue that climbs. Our fee never does. The $299 is the same whether your protocol settles at the lowest effective dose or climbs to the top of the range and the pharmacy bills you directly at its own price with no markup from us. We make money when you get healthier, not when your dose gets stronger. If a future approved retatrutide is genuinely the better clinical choice for you, choosing it costs us nothing and choosing tirzepatide earns us nothing extra.
The objection: my dose keeps climbing and so does the bill everywhere else
Plenty of patients arrive with this history. They started a semaglutide or tirzepatide subscription at one price, then titrated up and watched the monthly cost climb with each strength, because the subscription was priced by the dose. Some hit a plateau on a GLP-1 they already take and were told the only answer is the next dose up.
The clinically honest answer is that dose escalation is sometimes right and often reflexive. Titration exists to manage side effects and find the least medicine that produces the most result and a 90-day Biomarker Audit gives that decision a measurement to rest on instead of a renewal date. On our membership the titration conversation happens between you and your clinician with no price attached to the answer, because our revenue does not move either way. If the lowest dose is holding your results, the cheapest and healthiest path is to stay there.
Who should wait and who should start now
Waiting makes sense if your weight and metabolic markers are stable and you can tolerate the uncertainty, because joining a Lilly trial or simply starting on an approved drug later both remain open to you. Starting now makes sense if your A1c is climbing, if weight is driving sleep apnea or joint problems or if you have been circling this decision for a year while the trend line worsened. An approved drug with a known safety profile beats a hypothetical stronger drug you would be buying blind.
If you want to see whether our clinical approach fits your situation, the eligibility assessment comes before checkout and before any charge. You can also read the definitive guide to Cardiometabolic Optimization or our GLP-1 pricing guide before deciding anything.
Frequently Asked Questions
Is retatrutide FDA approved as of 2026?
No. Retatrutide remains investigational with phase 3 trials ongoing. There is no approved product, no label and no legal compounded version. Anything sold online as retatrutide today is an unapproved product outside the FDA's safety system.
How much more weight does retatrutide lose than tirzepatide?
The honest answer is that we do not know yet. Phase 2 retatrutide showed roughly 24 percent average weight loss at 48 weeks while phase 3 tirzepatide showed about 22.5 percent at 72 weeks. Different trials and durations make direct comparison unreliable and head-to-head data does not exist.
Is compounded retatrutide legal?
No. Compounding a copy of a drug is only permitted under limited conditions tied to FDA-approved drugs. With no approved retatrutide there is no basis for legal compounding. Any compounded retatrutide vial is illegal and unverified.
What does tirzepatide cost per month without insurance?
Cash-pay vial pricing for Zepbound through LillyDirect and major pharmacies commonly starts in the low hundreds per month for the lowest doses, with higher doses costing more. Pricing changes, so verify current pharmacy pricing before filling. The pharmacy sets and collects that price. GoodLife Health takes no markup on it.
Why not just wait for retatrutide instead of starting tirzepatide?
If your metabolic risk is active and rising, waiting means carrying the risk for another year or two while trials finish. Tirzepatide has an approved label, a known side-effect profile and three years of real-world use. You can switch or add options later if a better drug is approved.
Does GoodLife Health sell retatrutide?
No. We prescribe branded, FDA-approved medication only, billed by the pharmacy at pharmacy cost. When and if retatrutide is approved, it will be evaluated by our clinical protocols like any other approved drug.
What does the membership cost if I take tirzepatide?
The membership is one flat $299 a month for the doctor with a first charge of $598 covering the first two months. The medication is a separate charge billed by your pharmacy at its own price. Our fee does not change when your dose does.
Related Guides
- The GLP-1 pricing guide: Wegovy, Zepbound, Ozempic
- Medical weight loss at GoodLife Health
- Cardiometabolic optimization: the definitive guide
- What a Biomarker Audit includes
References
- Jastreboff AM et al., Triple-Hormone-Receptor Agonist Retatrutide for Obesity, a Phase 2 Trial, New England Journal of Medicine, 2023. doi.org/10.1056/NEJMoa2301972
- Jastreboff AM et al., Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), New England Journal of Medicine, 2022. doi.org/10.1056/NEJMoa2206038
- FDA, alerts on dosing errors and adverse events with compounded GLP-1 products. fda.gov